This double-blind, randomized, placebo-controlled trial assessed the effects of a dairy-based beverage containing 250 mg of dispersible baker’s yeast β-glucan (Wellmune®) on upper respiratory tract infections (URTIs) in marathon runners. Participants consumed the beverage daily for 45 days before and after the marathon. While the number and duration of URTI
